secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2021-09-13T23:59:59+00:00
Accession:  0001193125-21-270847
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics appoints Norman LaFrance as CMO, effective Dec 8, 2021
------------------------------------------------------------------------

- Dr. LaFrance will receive $440K base salary, 35% target bonus, and options for 120K shares vesting over 4 years.
- He brings 40 years in nuclear medicine and pharma, previously CMO at Jubilant Pharma Ltd.
- Appointment effective Dec 8, 2021; LaFrance will lead clinical development, regulatory, and medical affairs.
- Severance package includes 12 months salary + target bonus + COBRA premium if terminated without cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312521270847/0001193125-21-270847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312521270847/d151447d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-270847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer